Eczema patients who switched to upadacitinib had results like those who stayed
☕ Includes a question for the family ↓
EczemaPart of a story we are following · 6 articles · See every update
If your current eczema treatment is not controlling your skin and itch well enough, you may wonder about switching. This study offers a look at that. In a 52-week follow-up study of patients with moderate-to-severe eczema, those who switched from dupilumab to upadacitinib had safety results and skin and itch relief much like those who had been on upadacitinib all along.
Eczema is also called atopic dermatitis. Many people with it still do not get enough control from the treatments available. This study looked at what happens when you change course.
How the study worked
This was a follow-up to a phase 3b trial called Heads Up. In that trial, patients with moderate-to-severe eczema took either dupilumab (300 mg) or upadacitinib (30 mg) for 24 weeks. Those who finished could then join an extension and take upadacitinib (30 mg) for 52 more weeks. The results were published on November 20, 2026 in the J Am Acad Dermatol. Everyone knew which drug they were taking, which is the main limit of this kind of study.
What they found
The researchers compared two groups. One had stayed on upadacitinib the whole time. The other had switched from dupilumab to upadacitinib at the start of the extension.
Safety came first. The safety picture was similar in both groups. It also matched what earlier eczema studies had already shown. People who switched did not run into new or unexpected problems.
Then came the skin. Among patients who stayed on upadacitinib, skin clearance and itch relief held steady through the full 52 weeks of the extension. Their gains did not fade over time.
The patients who switched caught up. By the end of the extension, their skin and itch results were generally comparable to those of the patients who had been on upadacitinib continuously. In plain terms, starting upadacitinib after dupilumab got them to about the same place.
The authors conclude that upadacitinib may offer a safe, effective option for managing moderate-to-severe eczema.
What does “open-label” mean?
In many drug studies, neither the patients nor the doctors know who gets which treatment. That helps keep expectations from coloring the results. In an open-label study, everyone knows what is being taken. This design is common for follow-up studies like this one, where the goal is to see how people do over a longer stretch. The results here are a solid picture of safety and skin and itch response after a switch.
What you can do today
If your eczema is not settled, start collecting the facts your doctor will want. This week, take a clear photo of your worst patches and jot down how itchy your days and nights are. Bring both to your next appointment and ask whether switching treatments is an option for you.
For clinicians and researchers
Design: Open-label extension of the phase 3b Heads Up trial (NCT04195698): adults with moderate-to-severe atopic dermatitis who finished 24 weeks of dupilumab 300 mg or upadacitinib 30 mg then received upadacitinib 30 mg for 52 weeks. The comparison was switchers versus continuous upadacitinib.
Main result: Upadacitinib safety profiles were similar between patients who switched from dupilumab and those on continuous treatment. Skin clearance and itch outcomes at OLE end were generally comparable between groups; no effect sizes or confidence intervals are given in the abstract.
Main limitation: Open-label design without a blinded comparator during the extension, so bias in reporting of efficacy and safety cannot be excluded.
How it fits: Extends earlier Mongevity coverage of newer targeted eczema drugs by addressing what happens after switching from one targeted therapy to another. Eczema: newer targeted drugs went with fewer hospital and ER visits · Easing down your eczema medicine often keeps skin calm, review finds
Open question: Blinded, controlled comparisons are needed to establish whether switching to upadacitinib outperforms staying on dupilumab, and whether benefits persist beyond 52 weeks.
Trial registry: NCT04195698
Talk about it at home
Scientists followed people with eczema, a condition that makes skin dry, red and very itchy, for many months. Some kept the same treatment the whole time, and others changed to a new treatment partway through. By the end, both groups had calmer skin and less itch, a bit like families who take different roads to the same park and still arrive together.
Ask a grandparent or an older neighbor about a time they changed something familiar, like a school, a recipe or the way to work, and how they figured out whether the change was better. Did they know right away, or did they have to wait and see?
Try it at home
Keep exploring
Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.
Cite this article
Mongevity Desk. Eczema patients who switched to upadacitinib had results like those who stayed. Mongevity. Published November 21, 2026. Accessed November 22, 2026. https://mongevity.science/skin/2026/11/switching-dupilumab-to-upadacitinib-eczema/Mongevity Desk. Eczema patients who switched to upadacitinib had results like those who stayed [Internet]. Mongevity; 2026 Nov 21 cited 2026 Nov 22]. Available from: https://mongevity.science/skin/2026/11/switching-dupilumab-to-upadacitinib-eczema/Mongevity Desk. (2026, November 21). Eczema patients who switched to upadacitinib had results like those who stayed. Mongevity. https://mongevity.science/skin/2026/11/switching-dupilumab-to-upadacitinib-eczema/
<a href="https://mongevity.science/skin/2026/11/switching-dupilumab-to-upadacitinib-eczema/">Eczema patients who switched to upadacitinib had results like those who stayed</a>
Free to share or quote with credit and a link.
Questions and answers
- What did this study look at?
- It followed patients with moderate-to-severe eczema for 52 weeks. Some stayed on upadacitinib and others switched to it from dupilumab.
- Was switching from dupilumab to upadacitinib safe?
- In this open-label study, safety results were similar in patients who switched and those who stayed on upadacitinib, and they matched earlier eczema studies.
- Did skin and itch improve after switching?
- By the end of the 52 weeks, skin and itch results in the patients who switched were generally comparable to those who had stayed on upadacitinib.
- What does open-label mean?
- It means patients and doctors both knew which drug was being taken. This is common in follow-up studies.




